Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

225.08USD
1 Dec 2020
Change (% chg)

$0.00 (-0.00%)
Prev Close
$225.08
Open
$224.88
Day's High
$225.78
Day's Low
$222.80
Volume
1,018,783
Avg. Vol
1,173,336
52-wk High
$264.97
52-wk Low
$177.05

Latest Key Developments (Source: Significant Developments)

Amgen Says Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Saturday, 29 Aug 2020 

Aug 29 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES POSITIVE DATA FROM PHASE 3B STUDY OF REPATHA® (EVOLOCUMAB) IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AT ESC CONGRESS 2020.AMGEN INC - FIRST PHASE 3 TRIAL EVALUATING A PCSK9 INHIBITOR WHEN ADDED TO LIPID-LOWERING THERAPY IN PEDIATRIC HEFH POPULAT.AMGEN INC - REPATHA SIGNIFICANTLY REDUCED LDL-C AND IMPROVED ALL SECONDARY LIPID PARAMETERS.AMGEN INC - NO NEW SAFETY RISKS WERE IDENTIFIED.AMGEN -STUDY SHOW IN PEDIATRIC PATIENTS WITH HEFH, MONTHLY TREATMENT WITH REPATHA REDUCED LDL-C BY MEAN 38.3% FROM BASELINE COMPARED TO PLACEBO.  Full Article

Ligand Announces Amgen’S Kyprolis Approved By FDA To Treat Multiple Myeloma
Monday, 24 Aug 2020 

Aug 24 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ANNOUNCES AMGEN’S KYPROLIS® APPROVED BY FDA AS COMBINATION REGIMEN WITH DARZALEX® AND DEXAMETHASONE IN ONCE- AND TWICE-WEEKLY DOSING REGIMENS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.LIGAND PHARMACEUTICALS - AMGEN HAS SUBMITTED ADDITIONAL MARKETING APPLICATIONS GLOBALLY FOR KYPROLIS.  Full Article

Amgen Says FDA Approves New Kyprolis Combination Regimen With Darzalex And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens
Friday, 21 Aug 2020 

Aug 20 (Reuters) - Amgen Inc ::FDA APPROVES NEW KYPROLIS® (CARFILZOMIB) COMBINATION REGIMEN WITH DARZALEX® (DARATUMUMAB) AND DEXAMETHASONE IN BOTH ONCE- AND TWICE-WEEKLY DOSING REGIMENS.AMGEN INC - APPROVAL BASED ON CANDOR AND EQUULEUS STUDIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.  Full Article

Arrowhead Pharma Earns $20 Mln Payment From Amgen For Start Of Trial Of AMG 890
Wednesday, 29 Jul 2020 

July 29 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS EARNS $20 MILLION MILESTONE PAYMENT FROM AMGEN FOR START OF PHASE 2 TRIAL OF AMG 890.ARROWHEAD PHARMACEUTICALS - EARNED $20 MILLION MILESTONE PAYMENT FROM AMGEN FOLLOWING ADMINISTRATION OF FIRST DOSE OF AMG 890 IN PHASE 2 CLINICAL STUDY.  Full Article

Amgen Announces 2020 Third Quarter Dividend
Friday, 24 Jul 2020 

July 23 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 2020 THIRD QUARTER DIVIDEND.SETS QUARTERLY DIVIDEND OF $1.60PER SHARE.  Full Article

Moderna Appoints David Meline As Chief Financial Officer
Thursday, 4 Jun 2020 

June 4 (Reuters) - Moderna Inc ::DAVID MELINE JOINS MODERNA AS CHIEF FINANCIAL OFFICER.MODERNA INC - MELINE JOINS MODERNA FROM AMGEN.MODERNA INC - MELINE SERVED AS AMGEN CFO AND EVP FROM 2014 THROUGH 2019.  Full Article

FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Friday, 8 May 2020 

May 8 (Reuters) - Amgen Inc ::FDA GRANTS FAST TRACK DESIGNATION FOR OMECAMTIV MECARBIL IN HEART FAILURE.AMGEN - TOP-LINE RESULTS FROM GALACTIC-HF ARE EXPECTED IN Q4 2020.  Full Article

Amgen Announces Positive Top-Line Results From Otezla® Phase 3 Advance Study In Mild-To-Moderate Plaque Psoriasis
Wednesday, 6 May 2020 

May 6 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OTEZLA® (APREMILAST) PHASE 3 ADVANCE STUDY IN MILD-TO-MODERATE PLAQUE PSORIASIS.AMGEN INC - STUDY SHOWED THAT ORAL OTEZLA 30 MG TWICE DAILY ACHIEVED A STATISTICALLY SIGNIFICANT IMPROVEMENT, COMPARED WITH PLACEBO.AMGEN INC - ADVERSE EVENTS OBSERVED IN THIS TRIAL WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF OTEZLA.AMGEN INC - OTEZLA TREATMENT RESULTED IN SIGNIFICANT IMPROVEMENTS IN MEASURES OF MILD-TO-MODERATE PSORIASIS COMPARED WITH PLACEBO.  Full Article

Amgen Inc Says Kyprolis Patents Upheld Against Generic Manufacturer
Tuesday, 5 May 2020 

May 5 (Reuters) - Amgen Inc ::AMGEN INC - KYPROLIS (CARFILZOMIB) PATENTS UPHELD AGAINST GENERIC MANUFACTURER.AMGEN - DECISION WILL PREVENT CIPLA FROM MAKING, USING, SELLING OR IMPORTING GENERIC VERSION OF KYPROLIS UNTIL EXPIRATION OF PATENTS.  Full Article

Amgen Establishes Wholly-Owned Affiliate In Japan
Wednesday, 1 Apr 2020 

March 31 (Reuters) - Amgen Inc ::AMGEN ESTABLISHES WHOLLY-OWNED AFFILIATE IN JAPAN.CONSUMMATED PURCHASE FROM ASTELLAS OF 49% OF SHARES OF AMGEN ASTELLAS BIOPHARMA K.K., JOINT VENTURE BETWEEN CO AND ASTELLAS.  Full Article

Photo

Amgen, AstraZeneca say experimental asthma drug meets trial goal

Drugmakers Amgen Inc and AstraZeneca Plc said on Tuesday a pivotal trial found that their experimental medication tezepelumab significantly reduced asthma attacks for people with severe forms of the respiratory condition compared to a placebo.